Молекулярно-генетические механизмы формирования лекарственной устойчивости при терапии рака предстательной железы
George Sergeevich Krasnov, Alexey Alexandrovich Dmitriev, А. Ф. Садритдинова et al. · Molecular Biology · 2015
The major problem in prostate cancer treatment is the development of drug resistance and especially important, cross-resistance. The mechanisms of drug resistance, which are divided into ligand-dependent (requiring the presence of androgens in the cell) and independent (not requiring the presence of androgens) are reviewed. The mechanisms are mainly represented with mutations of the androgen receptor and expression of aberrant constitutively active splice variants, as well as up-regulation of genes involved in androgens synthesis.
Cited by 7 works. doi:10.7868/s0026898415050110
Authors
- George Sergeevich Krasnov
- Alexey Alexandrovich Dmitriev
- А. Ф. Садритдинова
- Н. Н. Волченко
- Elena N. Slavnova
- Т. В. Данилова
- Anastasiya V. Snezhkina
- Nataliya V. Melnikova
- Maria Fedorova
- Valentina A. Lakunina
- А. А. Белова
- B. Yа. Alekseev
- А. Д. Каприн
References
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer
- Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor